PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
30655284-0	2019	IL-17F, rather than IL-17A, underlies airway inflammation in a steroid-insensitive toluene diisocyanate-induced asthma model.	Steroids	63-70	interleukin 17F	Mus musculus	0-6
32753746-4	2020	IL-17F signals via the IL-17RA and -RC subunits in beta-cells and in combination with other inflammatory cytokines induces expression of chemokine transcripts, suppresses the expression of beta-cell identity genes and impairs glucose stimulated insulin secretion.	Glucose	226-233	interleukin 17F	Mus musculus	0-6
31916050-6	2020	Additionally, Y-27632 treatment significantly decreased CD68 and proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-17F (IL-17F), and interleukin-6 (IL-6).	Y 27632	14-21	interleukin 17F	Mus musculus	170-185
31916050-6	2020	Additionally, Y-27632 treatment significantly decreased CD68 and proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-17F (IL-17F), and interleukin-6 (IL-6).	Y 27632	14-21	interleukin 17F	Mus musculus	187-193
32391010-4	2020	IL-17A levels reduced but IL-17F levels increased significantly in the colorectum of Arg myeKO mice, leading to severe tissue damage and high risk of mortality rate.	Arginine	85-88	interleukin 17F	Mus musculus	26-32
31288049-10	2019	CONCLUSION: WBR is effective in the imiquimod-induced psoriasis-like inflammation mouse model with the efficacy arising from its proliferation inhibition of Th1/Th17 cells and epidermal keratinocytes via the down-regulation of the relevant inflammatory cytokines such as IL-23, IL-17A, and IL-17F.	Imiquimod	36-45	interleukin 17F	Mus musculus	290-296
33244669-2	2021	Results showed that compared with the control group, no differential expression proteins (DEPs) were found in the 1 mmol/L fluoride group; however, eight DEPs were upregulated in the 2.5 mmol/L fluoride group, including macrophage inflammatory protein-3alpha (MIP-3alpha), interleukin-21 (IL-21), IL-13, IL-17F, IL-28A, transforming growth factor type beta 1 (TGF-beta1), IL-23, and IL-17A.	Fluorides	194-202	interleukin 17F	Mus musculus	304-310
33244669-3	2021	In addition, five DEPs (MIP-3alpha, IL-13, IL-21, TGF-beta1, and IL-17F) were upregulated in the 2.5 mmol/L fluoride group compared with the 1 mmol/L fluoride group.	Fluorides	108-116	interleukin 17F	Mus musculus	65-71
30655284-0	2019	IL-17F, rather than IL-17A, underlies airway inflammation in a steroid-insensitive toluene diisocyanate-induced asthma model.	Toluene 2,4-Diisocyanate	83-103	interleukin 17F	Mus musculus	0-6
30655284-2	2019	Toluene diisocyanate (TDI) is one of the leading allergens of asthma that induces both T-helper Th2 and Th17 responses, and is often associated with poor responsiveness to steroid treatment in the clinic.We sought to evaluate the effects of inhaled and systemic steroids on a TDI-induced asthma model and to find how interleukin (IL)-17A and IL-17F function in this model.	Toluene 2,4-Diisocyanate	0-20	interleukin 17F	Mus musculus	342-348
30655284-6	2019	Recombinant IL-17A and IL-17F showed opposite effects to the monoclonal antibodies.IL-17A and IL-17F exert distinct biological effects during airway inflammation of a TDI-induced asthma model, which is unresponsive to both inhaled and systemic steroids.	Steroids	244-252	interleukin 17F	Mus musculus	94-100
29073354-9	2017	The upregulated expressions of IL-23, IL-17A, and IL-17F genes were suppressed by vanillin, with fold changes of -3.07 +- 0.08, -2.06 +- 0.21, and -1.62 +- 0.21, respectively.	vanillin	82-90	interleukin 17F	Mus musculus	50-56
30121880-8	2019	Moreover, expression of mRNA that are characteristic of the Th17 signature, such as IL-17A and IL-17F in the colon, were inhibited by TAK-828F, while the expression of IL-10, an anti-inflammatory cytokine, was increased.	TAK-828F	134-142	interleukin 17F	Mus musculus	95-101
29068000-0	2018	beta-Glucans in food modify colonic microflora by inducing antimicrobial protein, calprotectin, in a Dectin-1-induced-IL-17F-dependent manner.	beta-Glucans	0-12	interleukin 17F	Mus musculus	118-124
29068000-8	2018	These observations suggest that food-derived beta-glucans control the specific commensal microbiota via the Dectin-1-IL-17F-calprotectin axis to maintain the intestinal homeostasis.	beta-Glucans	45-57	interleukin 17F	Mus musculus	117-123
30662553-11	2019	After topical administration to mice, the HA-ES group showed an alleviation of inflammation symptoms; lower TNF-alpha, IL-17A, IL-17F, IL-22, and IL-1beta mRNA levels; and lower CCR6 protein expression compared to the ES and PGS groups.	Einsteinium	45-47	interleukin 17F	Mus musculus	127-133
28358365-6	2017	Oral administration of madecassic acid decreased the percentage of Th17 cells and downregulated the expression of RORgammat, IL-17A, IL-17F, IL-21 and IL-22 and increased the percentage of Treg cells and the expression of Foxp3 and IL-10 in the colons of mice with colitis, but it did not affect Th1 and Th2 cells.	madecassic acid	23-38	interleukin 17F	Mus musculus	133-139
24286371-4	2014	Real-time polymerase chain reaction showed that the mRNA levels of IL-17A, IL-17F, IL-22, IL-1beta, IL-6 and TNF-alpha in ear skin were significantly decreased by clobetasol.	Clobetasol	163-173	interleukin 17F	Mus musculus	75-81
28584821-3	2017	RESULTS: DSS-resistant BALB/c mice were characterized by low levels of IFN-gamma and TNF-alpha but high levels of IL-4, IL-6, IL-10, IL-17A, IL-17F, and colon lamina propria and mesenteric lymph node (MLN) CD4+CD25+FoxP3+ T cells when compared to C57BL/6 mice.	Dextran Sulfate	9-12	interleukin 17F	Mus musculus	141-147
27449383-11	2016	AZM treatment improved splenomegaly, decreased the populations of Th17 and gammadelta T cells, and reduced the expression of cytokines known to be involved in the pathogenesis of psoriasis, such as IL-17A, IL-17F, IL-22 and IL-23, in the skin and spleen.	Azithromycin	0-3	interleukin 17F	Mus musculus	206-212
27089940-4	2016	We found that RA had a dramatic suppressive effect on IL-17A and IL-17F production by gammadelta T cells stimulated with IL-1beta and IL-23.	Tretinoin	14-16	interleukin 17F	Mus musculus	65-71
27353073-8	2016	Topical compd3 penetrates the skin and suppresses phorbol myristate acetate-induced IL-13, IL-22, IL-17F, and IL-23 transcription and calcipotriol-induced thymic stromal lymphopoietin expression in mouse skin.	Tetradecanoylphorbol Acetate	50-75	interleukin 17F	Mus musculus	98-104
26895034-7	2016	MCDD feeding augmented hepatic IL-17RA expression and significantly increased hepatic infiltration of macrophages and IL-17A and IL-17F producing CD4+ and CD8+ T cells in WT mice.	mcdd	0-4	interleukin 17F	Mus musculus	129-135
26336925-6	2015	Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma.	Cholecalciferol	31-41	interleukin 17F	Mus musculus	237-243
27401543-4	2016	RESULTS: TPA led to localized skin inflammation with increased epidermal thickness, infiltration of inflammatory-like cells and augmented tissue interleukin-17F levels.	Tetradecanoylphorbol Acetate	9-12	interleukin 17F	Mus musculus	145-160
25341726-11	2015	LtxA caused resolution of disease in mice, as demonstrated by a decrease in BALF WBCs, a reduction in pulmonary inflammation and tissue remodeling, and a decrease in proinflammatory cytokines IL-4, IL-5, IL-9, IL-17F, and IL-23alpha in lung tissue.	ltxa	0-4	interleukin 17F	Mus musculus	210-216
22137260-10	2012	The C-DSS group had higher percentages of blood interleukin (IL)-17A, IL-17F, IL-22, IL-4 and interferon-gamma than the NC group.	c-dss	4-9	interleukin 17F	Mus musculus	70-76
23825622-6	2013	Real-time PCR showed that mRNA levels of IL-17A, IL-17F, IL-22, IL-1beta, IL-6 and TNF-alpha cytokines were decreased significantly by curcumin in ear skin, an effect similar to that of clobetasol.	Curcumin	135-143	interleukin 17F	Mus musculus	49-55
23296151-11	2013	Treatment with digoxin also markedly suppressed the mRNA expression levels of IL-17A, IL-17F, and granulocyte-macrophage colony-stimulating factor, reduced the number of Th17 cells, and induced Treg expansion in the allografts.	Digoxin	15-22	interleukin 17F	Mus musculus	86-92
22922441-7	2012	In vitro, SAHA reduced the proportion of Th17 cells in isolated CD4+ T-cell population and decreased expressions of IL-17A, IL-17F, STAT3 and RORgammat in these cells.	Vorinostat	10-14	interleukin 17F	Mus musculus	124-130
20881307-11	2011	IL-17A and IL-17F were significantly higher in the eyes of EAU-induced mice at day 7.	Water	59-62	interleukin 17F	Mus musculus	11-17
20974859-3	2010	Treatment of mice with an active ligand of vitamin D receptor (VDR), 1,25-dihydroxyvitamin D(3) (1,25D3), ameliorated experimental autoimmune encephalomyelitis, accompanied with reduced IL-17 and IL-17F expression.	1,25-dihydroxyvitamin D	69-92	interleukin 17F	Mus musculus	196-202
21858022-4	2011	RESULTS: We show that bleomycin or IL-1beta-induced lung injury leads to increased expression of early IL-23p19, and IL-17A or IL-17F expression.	Bleomycin	22-31	interleukin 17F	Mus musculus	127-133
20210523-4	2010	Moreover, SMMC-7721/RV-IL-17F exhibited a significant decrease in tumor size and microvessel density as compared to the SMMC-7721/RV control when transplanted in nude mice.	smmc	10-14	interleukin 17F	Mus musculus	23-29
20210523-4	2010	Moreover, SMMC-7721/RV-IL-17F exhibited a significant decrease in tumor size and microvessel density as compared to the SMMC-7721/RV control when transplanted in nude mice.	smmc	120-124	interleukin 17F	Mus musculus	23-29
20042461-8	2010	Additionally, we observed that IL-17A and IL-17F induced MAPK (p38 MAPK, ERK1/2, and JNK) activation and that pharmacological inhibitors of p38 MAPK (SB203580) and ERK1/2 (U0126), but not JNK (SP600125), blocked the IL-17A/IL-17F-mediated MCP-1 and MIP-2 release.	SB 203580	150-158	interleukin 17F	Mus musculus	42-48
20042461-8	2010	Additionally, we observed that IL-17A and IL-17F induced MAPK (p38 MAPK, ERK1/2, and JNK) activation and that pharmacological inhibitors of p38 MAPK (SB203580) and ERK1/2 (U0126), but not JNK (SP600125), blocked the IL-17A/IL-17F-mediated MCP-1 and MIP-2 release.	U 0126	172-177	interleukin 17F	Mus musculus	42-48
17452998-5	2007	Fully differentiated mouse THi cells also naturally secrete IL-17A/F as well as IL-17 and IL-17F homodimeric cytokines.	2-acetyl-4(5)-tetrahydroxybutylimidazole	27-30	interleukin 17F	Mus musculus	90-96
20042461-8	2010	Additionally, we observed that IL-17A and IL-17F induced MAPK (p38 MAPK, ERK1/2, and JNK) activation and that pharmacological inhibitors of p38 MAPK (SB203580) and ERK1/2 (U0126), but not JNK (SP600125), blocked the IL-17A/IL-17F-mediated MCP-1 and MIP-2 release.	pyrazolanthrone	193-201	interleukin 17F	Mus musculus	42-48
19170127-9	2009	Concomitant administration of Dex, a known NF-kappaB inhibitor, resulted in significantly down-regulated IL-1 beta-induced NF-kappaB/p65 activity, as well as reduced expression of chemokine receptors and IL-17F in mouse prostate tissue.	Dexamethasone	30-33	interleukin 17F	Mus musculus	204-210
19380832-6	2009	IMQ induced epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells.	Imiquimod	0-3	interleukin 17F	Mus musculus	55-61
17541285-12	2007	Further, the expression of IL-17 F was significantly attenuated by the treatment of mice with DEX.	Dexamethasone	94-97	interleukin 17F	Mus musculus	27-34
15477493-4	2005	The results showed first that a significant increase in the number of neutrophils was seen in the bronchoalveolar lavage fluids of IL-17F-transduced mice, concomitant with increased expression of genes encoding C-X-C chemokines and inflammatory cytokines when compared with mock and phosphate-buffered saline control animals.	Phosphate-Buffered Saline	283-308	interleukin 17F	Mus musculus	131-137
15477493-7	2005	A significant enhancement of ventilatory timing in response to inhaled methacholine was also seen in IL-17F-transduced, Ag-sensitized mice, whereas a small but significant increase was found in IL-17F-transduced, naive mice.	Methacholine Chloride	71-83	interleukin 17F	Mus musculus	101-107
34464701-24	2021	RESULTS: FJDH with copper was found to improve psoriasis-related pathological symptoms in a dose-dependent manner, possibly by inhibiting IL-23/Th17 cell axis and reducing inflammatory cytokines such as IL-17A, IL-17F, IL-22 and TNF-alpha.	Copper	19-25	interleukin 17F	Mus musculus	211-217
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	123-126	interleukin 17F	Mus musculus	46-52
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	172-175	interleukin 17F	Mus musculus	46-52
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	T16AInh-A01	180-191	interleukin 17F	Mus musculus	46-52
35216231-5	2022	Moreover, SeP treatment significantly attenuated the expression of key inflammatory cytokines, including interleukin (IL)-23, IL-17A, and IL-17F, in the dorsal skin of mice.	Phosphoserine	10-13	interleukin 17F	Mus musculus	138-144
34884834-8	2021	Moreover, in vivo imiquimod-induced psoriatic skin treated with ATCC12228EVs reduced the characteristic psoriatic skin features, such as acanthosis and cellular infiltrate, as well as VEGF-A, IL-6, KC, IL-23, IL-17F, IL-36gamma, and IL-36R expression in a more efficient manner than 983EVs; however, in contrast, Foxp3 expression did not significantly change, and IL-36 receptor antagonist (IL-36Ra) was found to be increased.	Imiquimod	18-27	interleukin 17F	Mus musculus	209-215
34884834-8	2021	Moreover, in vivo imiquimod-induced psoriatic skin treated with ATCC12228EVs reduced the characteristic psoriatic skin features, such as acanthosis and cellular infiltrate, as well as VEGF-A, IL-6, KC, IL-23, IL-17F, IL-36gamma, and IL-36R expression in a more efficient manner than 983EVs; however, in contrast, Foxp3 expression did not significantly change, and IL-36 receptor antagonist (IL-36Ra) was found to be increased.	atcc12228evs	64-76	interleukin 17F	Mus musculus	209-215
34180764-8	2021	The results showed that CS-RC nanoparticles via intranasal intervention significantly caused inhibition of mucus secretion and airway inflammatory cell infiltration, and reduced IL-4, IL-17, IL-17F levels in BALF.	Chitosan	24-26	interleukin 17F	Mus musculus	191-197
34587561-7	2021	In contrast, mice lacking IL-17F are resistant to DSS-colitis, partly attributable to alterations in intestinal microbiota that mobilize Tregs.	tregs	137-142	interleukin 17F	Mus musculus	26-32
34215679-3	2021	Here, we demonstrate the unexpected involvement of a posttranscriptional "epitranscriptomic" mRNA modification (N6-methyladenosine (m6A)) in regulating C/EBPbeta and C/EBPdelta in response to IL-17A, as well as IL-17F and TNFalpha.	N-methyladenosine	112-130	interleukin 17F	Mus musculus	211-217